Saili Yi

机构：Gilead Sciences (United States)

发表论文 2 篇 · 总被引 250 次 · h-index 2

代表论文

• Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation (2020 · Journal of Hepatology · 被引 230)
• Pharmacokinetics, Safety, and Tolerability of Selonsertib, an Apoptosis Signal-Regulating Kinase 1 (ASK1) Inhibitor, Following First-in-Human Single and Multiple Ascending Doses in Healthy Subjects (2020 · Clinical Pharmacokinetics · 被引 20)